Figure 2From: Predictive role of multiple gene alterations in response to cetuximab in metastatic colorectal cancer: A single center studyPFS on the basis of the number of tumor molecular alterations. A significant difference (p < 0.001) was observed among patients harboring no (5.5 months), one (2.9 months) or two (2.2 months) alterations.Back to article page